**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 17063**

**Columns: Review**

**Surgical strategies in paediatric inflammatory bowel disease**

Baillie CT *et al.* Surgical strategies in paediatric IBD

Colin T Baillie, Jennifer A Smith

**Colin T Baillie, Jennifer A Smith,** Department of Paediatric Surgery, Royal Liverpool Childrens Hospital, NHS Trust, Liverpool L12 2AP, United Kingdom

**Author contributions:** All authors contributed to the manuscript.

**Conflict-of-interest:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Dr. Colin T Baillie,** Consultant Paediatric Surgeon, Department of Paediatric Surgery, Royal Liverpool Childrens Hospital, NHS Trust, Eaton Rd, Liverpool L12 2AP, United Kingdom. colin.baillie@rlc.nhs.uk

**Telephone:** +49-231-9144880

**Fax:** +49-231-91448888

**Received:** February 10, 2015

**Peer-review started:** February 10, 2015

**First decision:** March 10, 2015

**Revised:** March 30, 2015

**Accepted:** April 9, 2015

**Article in press:**

**Published online:**

**Abstract**

Inflammatory bowel disease (IBD) comprises two distinct but related chronic relapsing inflammatory conditions affecting different parts of the gastrointestinal tract. Crohn’s disease is characterised by a patchy transmural inflammation affecting both small and large bowel segments with several distinct phenotypic presentations. Ulcerative colitis classically presents as mucosal inflammation of the rectosigmoid (distal colitis), variably extending in a contiguous manner more proximally through the colon but not beyond the caecum (pancolitis). This article highlights aspects of the presentation, diagnosis, and management of IBD that have relevance for paediatric practice with particular emphasis on surgical considerations. Since 25% of IBD cases present in childhood or teenage years, the unique considerations and challenges of paediatric management should be widely appreciated. Conversely, we argue that the organizational separation of the paediatric and adult healthcare worlds has often resulted in late adoption of new approaches particularly in paediatric surgical practice.

**Key words:** Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Paediatric; Surgery

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Approximately 25% of patients with inflammatory bowel disease have onset of symptoms in childhood or adolescence. The unique and often severe features of childhood presentation make treatment decisions challenging. The dogma of surgical conservatism in Crohn's disease is challenged in the specific instance of left sided colitis. Furthermore we argue that the separation of adult and paediatric inflammatory bowel disease practice may disadvantage children, delaying adaption of innovative treatments and timely transition.

Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Inflammatory bowel disease (IBD) comprises two distinct but related chronic relapsing inflammatory conditions affecting different parts of the gastrointestinal tract. Crohn’s disease (CD) is characterised by a patchy transmural inflammation affecting both small and large bowel segments with several distinct phenotypic presentations. Ulcerative colitis (UC) classically presents as mucosal inflammation of the rectosigmoid (distal colitis), variably extending in a contiguous manner more proximally through the colon but not beyond the caecum (pancolitis) except rarely when backwash ileitis features. This article highlights aspects of the presentation, diagnosis, and management of IBD that have relevance for paediatric practice with particular emphasis on surgical considerations. Since 25% of IBD cases present in childhood or teenage years, the unique considerations and challenges of paediatric management should be widely appreciated. Conversely, we argue that the organizational separation of the paediatric and adult healthcare worlds has often resulted in late adoption of new approaches particularly in paediatric surgical practice.

**INCIDENCE**

A prospective United Kingdom survey of childhood IBD showed that the incidence was 5.2 per 100000 children per year. In terms of disease distribution 60% were diagnosed as CD and 28% as UC. The remaining 12% could not be classified, and were labelled as indeterminate colitis (IC)[1]. The mean age at diagnosis was 12 years with 5% presenting at less than 5 years of age[2]. The United Kingdom data are similar to a systematic review of North American paediatric cohorts suggesting an incidence of 3-4 per 100000[3]. A recent systematic review comparing time-trend analyses across the age spectrum demonstrated that in 75% of CD studies and 60% of UC studies, the incidence of IBD had significantly increased[4].

**PATHOGENESIS**

A detailed analysis of progress in understanding the aetiology of IBD is beyond the scope of this article. Suggested mechanisms include the influence of a variety of possible environmental factors triggering an inflammatory response which then persists in a genetically susceptible individual, according to the Knudsen “two-hit” hypothesis. A number of candidate IBD genes have been identified since the CARD15/NOD2 gene was identified on chromosome 16[5]. By 2011, genome-wide association studies had demonstrated 99 non-overlapping gene loci associated with CD and UC, including 28 that are shared, suggesting common mechanisms of pathogenesis[6]. These studies have provided “molecular pointers” to the underlying pathophysiological processes which might be implicated in IBD, including epithelial barrier function, epithelial cell regeneration, microbial defence, innate immune regulation, generation of reactive oxygen species, autophagy, and regulation of adaptive immunity. Even at the level of the individual candidate gene locus, these interactions are complex. For example NOD2 is currently implicated in autophagy, viral recognition and T cell activation[7]. The genes implicated in UC and CD overlap, as do those implicated in childhood- and adult-onset IBD, indicating both common mechanisms of pathogenesis and genetic predisposition. Disease concordance rates in monozgotic twin studies are 10%-15% in UC and 30%-35% in CD, suggesting that non-genetic factors may have greater influence in the pathogenesis of UC[8]. The relationship between genotype and either locational phenotype or behaviour of disease are complex and have at times yielded conflicting results.

The NOD2/CARD15 gene association with CD has been most extensively studied and has been linked to defective Toll receptor-mediated macrophage opsonisation of pathogenic bacteria. NOD2 variants have been associated with the fibrostenosing phenotype, more aggressive disease progression, and ileocaecal presentation[9], although their relation to surgical recurrence has produced contradictory results. “Wild type” gene expression at this locus has been correlated with more favourable response of Crohn’s fistulae to antibiotics[10]. In respect of perianal disease phenotype, the influence of dysfunctional gene expression for both the carnitine/organic cation transporter *OCTN*[11], and immunity-related GTP-ase family M protein (*IRGM)*[12,13] on chromosome 5q31 (IBD5) seem to be more specifically related to both fistula and abscess incidence, possibly via defective oxygen burst-mediated bactericidal function, and defects in bacterial autophagy respectively. Although IBD has a multigenic aetiology, each of modest contribution to overall pathogenesis, it remains possible that future advances in genotype studies will identify behavioural subtypes which have significant therapeutic consequence.

Basic science research has focussed on the gut/environmental interface and the various mechanisms maintaining its integrity, the inflammatory process including cell signalling, cytokine responses, the specific gut microbiome and cellular immune defences. Various epidemiological studies have implicated diet, ethnicity, socioeconomic status, smoking, migration and vaccination status in the pathogenesis of CD[14].

**DIAGNOSIS AND MEDICAL MANAGEMENT**

The configuration of United Kingdom medical services has resulted in the paediatric gastroenterologist being the focal point of referral for children with suspected IBD. Moreover, the specialist endoscopic skills required for diagnosis are now less readily available within paediatric surgical departments[15]. Thus the diagnosis of IBD in childhood is largely the domain of the gastroenterologist. Despite this it is vitally important that any surgeon managing children should be aware of the common presenting features of inflammatory bowel disease, both to ensure that the child is appropriately investigated and to avoid premature ill-conceived surgical intervention. The most common presentations to surgical services are for investigation of rectal bleeding, anal pain, and acute exacerbations of abdominal pain. It is very uncommon for surgical intervention to be required before appropriate diagnostic endoscopic and radiological tests have established the type and extent of IBD, allowing opportunity for appropriate targeted medical management.

Any surgeon treating children with IBD should have a working knowledge of the medical treatment options, their efficacy, side effects and psychosocial impact, to ensure that when a surgical option is under consideration with its potential attendant morbidity, the child and his parents are fully aware of the advantages and disadvantages of all management strategies. Joint clinics staffed by a gastroenterologist, specialist surgeon, dietician and nurse specialist constitute the ideal venue for difficult discussions where clinical decision making is often highly nuanced.

**DIAGNOSIS**

All children suspected of IBD require full history and examination including assessment of growth velocity and pubertal staging. A minority (25%) of children with CD present with the classic triad of abdominal pain, diarrhoea and weight loss. A high index of suspicion should be maintained in children presenting with vague complaints such as lethargy, anorexia and impaired growth or delayed puberty[2]. The development of standardised diagnostic criteria (the Porto criteria) by the IBD working group of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) has done much to ensure uniformity in diagnosis and management[16].

The gold standard in diagnosis is combined upper and lower gastrointestinal endoscopy (including ileal intubation), together with small bowel radiology. Additional laboratory investigations are adjunctive, but should always include inflammatory markers (ESR, platelets and CRP), nutritional markers (albumin), and liver function tests because of the association of primary sclerosing cholangitis with UC. Stool cultures are mandatory to exclude an infective colitis. Absence of elevated faecal inflammatory surrogate markers calprotectin and lactoferrin make active bowel inflammation unlikely. In children younger than 2 years and in those with atypical presentation immunological tests are required to exclude chronic granulomatous disease, common variable immune deficiency, Wiskott-Aldrich syndrome and other immunodeficiency states. Increasing experience with MR enterography, the lack of exposure to radiation, and the utility of MRI in the evaluation of perianal CD, all favour this study over contrast meal and follow through for the radiological evaluation of the small bowel. Capsule endoscopy is showing promise as an adjunct in cases of diagnostic difficulty, but carries the risk of obstruction if the capsule becomes impacted at an occult area of narrowing. Lack of sensitivity of technetium leukocyte scintigraphy has largely consigned this test to being of historical interest only.

**CLASSIFICATION**

The Montreal classification of IBD classifies CD by virtue of age, location and behaviour (inflammatory, structuring or fistulating)[17]. It subdivides UC based on the extent and severity of the colitis. More detailed scoring systems have both prognostic and comparative value for research purposes. The paediatric CD activity index (PCDAI) is based on clinical parameters from recent history, examination findings, laboratory results, growth parameters and extra-intestinal manaifestations[18]. The paediatric ulcerative colitis activity index (PUCAI) incorporates 6 clinical items and is therefore easy to use[19]. Any classification for CD can be particularly frustrating for the surgeon. The issue for the surgeon is the difference between macroscopic and microscopic disease. The danger of the classification system is that equal weight is given to asymptomatic microscopic disease, and the macroscopic disease which is actually causing the symptoms. Thus, for example, a patient may be labelled as having pan-intestinal CD when he is actually symptomatic from stricturing ileocaecal disease and merely has asymptomatic microscopic disease elsewhere. As with every classification system, its intrinsic usefulness is dependent on its clinical significance for decision making.

**MEDICAL MANAGEMENT**

***Ulcerative colitis***

The medical approach to UC in childhood is dependent on the extent and severity of the colitis. Presentation with pan-colitis is twice as common (60%-80%) as adults[20], and for this reason steroid therapy is most often initiated. In less severe colitis, oral or rectal therapy with aminosalicylic acid (5-ASA) derivatives would represent both first line and maintenance therapy after induction of remission. Oral ASA therapy may be combined with topical treatment but often the rectal route is unacceptable to the child. Steroids do not have a role in maintaining remission, and therefore thiopurines (azathioprine or mercaptopurine) are used as immunomodulators either alone or alongside 5-ASA. Thiopurines may take up to 10-14 wk to achieve therapeutic effect and are usually started alongside steroids for this reason. Infliximab should be considered in steroid-dependent UC, resistant to 5-ASA or thiopurines. Adalimumab may be substituted in patients who have lost response to or are intolerant of infliximab. Less commonly, cyclosporin or tacrolimus may be used in acute severe colitis as a bridging therapy before thiopurine efficacy. There is currently no evidence to support using methotrexate, antibiotics or probiotics for the induction or maintenance of remission in children. Similarly plasmapheresis remains controversial as a therapeutic option for severe childhood UC[21].

***CD***

Since CD has many phenotypic variants, medical therapeutic strategies are, to a certain extent, tailored both to disease location and to the severity of symptoms. Perianal CD (PACD) is discussed separately in this article since it is of particular interest to the surgeon, and only the broad principles of medical management of paediatric CD are discussed below. Both steroids and exclusive enteral nutrition (EEN) are considered equally effective in inducing remission. There is no difference in efficacy of either elemental or polymeric formula feeds which both avoid the unpleasant side-effects of steroids and promote nutrition. Prolonged courses of EEN are difficult to sustain both due to taste and dietary boredom. In common with UC, remission is maintained with thiopurines which should be initiated at the onset of either dietary of steroid therapy. Unlike UC, methotrexate is effective in maintaining remission in cases of thiopurine toxicity. 5-ASA treatment cannot be recommended in the management of CD, both because of lack of paediatric data, and lack of efficacy in adults. Infliximab may be used as second line induction and maintenance therapy in relapsing CD where EEN or steroids are losing effect, or where side effects of steroids are intolerable[22,23]. Infliximab is controversial in the setting of the stricturing CD phenotype, with some studies suggesting lack of efficacy[24], and others favouring its use[25]. It is entirely possible that the distinction lies between fibrous and inflammatory strictures with lack of efficacy in the former group. It has been the author’s experience that acute obstructive symptoms may rapidly respond to steroid therapy suggesting a significant inflammatory component in the aetiology of symptoms. Second line biological therapy may be effective in case of either loss of effect of infliximab or intolerance. The rates of surgical treatment of IBD in the “biologic era” have recently received attention in the literature, suggesting that the overall incidence of surgery has declined in those with mild disease, but that the incidence of surgery is unchanged in patients with severe disease[26].

**SURGICAL MANAGEMENT OF ULCERATIVE COLITIS**

The objective in both elective and emergency surgical interventions for UC is the removal of the colon. The most common indication for colectomy is failure of medical therapy whether due to frequent disease activation with relative short periods of remission, or unacceptability of the side-effects of medical therapy. Inadequate disease control may also be reflected by reduced growth velocity, delayed puberty, inadequate nutrition, poor bone mineralisation and loss of time from school. Although some extra-intestinal features of UC are improved by surgery, primary sclerosing cholangitis and sacroiliitis are not[27]. Colonic cancer per se does not feature in the indications for colectomy in childhood since the quoted risk is 2% at 10 years, 8% at 20 years and 18% at 30 years[28]. However, a French study noted a 3-fold increased risk of neoplasia (including colon cancer 2/698) in paediatric onset IBD patients over a median follow up of 11.5 years[29], and the Porto IBD group noted a number of treatment-related malignancies (mainly lymphoma)[30]. Body image concerns are significant barriers to surgery for many children and careful support form psychologists and stoma therapists may be necessary for them to accept even a temporary stoma. Colectomy rates at five years from diagnosis range between 14%[31] and 24%[32,33] in children.

Reconstructive (continent) surgery for UC was transformed in 1978 by the development of the ileal pouch anal anastomosis (IPAA) (see Figure 1) by Parks and Nicholls which is now the gold standard[34]. Since paediatric surgeons were at that time already familiar with straight ileoanal pull as an option for treatment of total colonic Hirschsprung’s disease[35], and also because of low patient numbers requiring colectomy for UC, they were generally late adopters of the IPAA. The most conservative approach for elective surgery is a 3-stage procedure performing total colectomy with end ileostomy, delaying completion proctectomy to the time of construction of IPAA, and covering this with a temporary ileostomy. Two-stage surgery either involves total colectomy and avoiding a covering ileostomy at the time of pouch formation (authors preference), or fashioning a primary pouch at the time of panproctocolectomy and covering this with an ileostomy. In the elective setting, total colectomy and end ileostomy was the most widely performed procedure in adult practice (guidelines American Society of Colon and Rectal Surgeons)[36], although panproctocolectomy, and primary pouch construction with covering ileostomy is rapidly gaining acceptance[37-39]. Clearly single stage surgery is feasible[40], but is associated with a higher risk of major complications such as anastomotic dehiscence, sepsis and late pouch failure[37]. Since the median number of pouch operations performed per year by United Kingdom paediatric surgeons specializing in IBD is 1 (range 0-4)[15], there is a natural tendency to opt for the most conservative elective operation and perform colectomy and end ileostomy. Children are usually transformed by this procedure and rapidly resume normal activity, including, most importantly, school attendance. Since significant symptoms from the retained rectum are infrequently encountered[41], the driver for restorative surgery is the child’s desire to lose the end ileostomy, which is usually counter-balanced by individual educational pressures and the child’s general sense of well-being.

The greater experience of IPAA within the adult sector and the fact that most children undergoing continent reconstruction will soon be transitioned into adult care, have prompted many surgeons to joint operate with adult colleagues at the time of pouch formation. Such cooperation both facilitates later transition and enables the sharing of technical expertise. Advances such as the double-stapled IPAA have been incorporated into paediatric practice with considerable reduction in operating time when compared with traditional hand-sewn IPAA. The complication rate has been shown to be unchanged and the functional performance of the reservoir marginally improved in the shift from the hand-sewn to the double-stapled anastomosis[42].

Large volume outcome data for IPAA within the paediatric sector are sparse with studies tending to compare the IPAA with straight pull through. A paediatric meta-analysis suggested a higher failure rate for straight (15%) over pouch (8%) pull through procedures, associated with both higher daily stool frequency and post-operative sepsis rates[39]. A multicentre analysis of 203 children undergoing straight (SIAA 112) and J pouch (JPAA 91) ileoanal anastomosis (mainly for UC) demonstrated significantly reduced daily stool frequency in the JPAA , although after 24 months the difference became less apparent (SIAA 8.4 *vs* JPAA 6.2)[43]. The mean daily defecation frequency 24 months after IPAA in a Finnish study was 3.3 ± 0.5, demonstrating that excellent short term functional results can be achieved in children[44].

***Morbidity***

The IPAA is associated with a high surgical complication rate. The Mayo clinic experience of intraoperative abandonment of IPAA (1789 cases) was 4.1%[45]. One large study including 151 children reported that one fifth of patients will have at least one complication in the first month after surgery[46]. This study focussed on pouchitis demonstrating a single episode in 48%, chronic refractory pouchitis in 7%, and pouch failure in 9%. The authors demonstrated that late diagnosed Crohns disease (15%) was an important determinant of poor outcome. In another paediatric series the complication rate was as high as 21/37 (57%); including stenosis of the IAA (2/37), pelvic abscess/sepsis (4/37), late fistula (3/37), early intestinal obstruction (7/37), late intestinal obstruction (11/37), pouch prolapse (1/37), wound complications 6/37, pouchitis (23/37), and recurrent pouchitis (13/37)[47]. Another paediatric study reported a high incidence (19%) of intestinal obstruction[48]. There is no reason to assume that the complication rates of IPAA in children should be different from those seen in adult practice where anastomotic dehiscence is observed in 5%-10%, pouch-vaginal fistula in 3%-16%, pouchitis in 24%-48%, and pouch failure at 5 years in 8.5%[38], as well as the risk of reduction in fertility in females, discussed in the next section. Long term follow up suggests overall cumulative pouch failure rates of 15% over 10-15 years. A proportion of these patients with outlet obstruction and low pouch capacity will be improved by abdominal salvage procedures[49]. There is very little experience in the paediatric surgical literature of revision pouch surgery which is a further strong argument for close links with high case load adult specialist units[15].

***Ileorectal Anastomosis***

The option of ileorectal anastomosis (IRA) (Figure 2) for UC is rarely considered in childhood. Potential advantages include a reduced stool frequency with improved faecal continence[50], improved fertility in females[51], and a reduced likelihood of impaired sexual functioning due to nerve injury during the pelvic dissection. This has to be balanced with the need for regular endoscopic surveillance and the potential for failure of medical control of the residual disease in the rectum.

The ultimate failure rate of IRA for UC is as high as 57%[52], but this does not argue against the procedure in females if time is gained for pregnancy before later restorative proctectomy. A meta-analysis has demonstrated that the rate of female infertility (15% in medically treated UC) rises to 48% after IPAA[53], although many of these “infertile” women could potentially achieve medically-assisted conception. Another systematic review demonstrated a more modest effect on infertility, with a rate of 12% before IPAA, and 26% thereafter (945 women in 7 studies). The same authors reported rates of sexual dysfunction (dyspareunia) in 8% preoperatively, compared with 25% after restorative surgery (419 women in 7 studies)[54]. One study looked at the effect of restorative proctectomy in childhood on later sexual function in adulthood concluding that rates of dysorgasmia and dyspareunia were not significantly different between girls undergoing surgical or medical management of UC. They authors also noted that sexual satisfaction was inversely correlated with faecal incontinence[55]. A study evaluating quality of life (QOL) after colectomy identified younger age at colectomy, diagnosis and survey to be associated with better QOL scores. The length of time post colectomy did not have any correlation with QOL[56].

**ACUTE SEVERE COLITIS**

The management of children presenting with acute severe colitis (ASC), identified by the requirement of intravenous steroid therapy, has been subject to little scrutiny in the literature. Cumulative colectomy rates in 99 children with ASC at discharge, 1 year, and 6 years, were 42%, 58% and 61% respectively[57]. Predictive factors significantly associated with corticosteroid failure include C-reactive protein, and the number of nocturnal stools on days 3 and 5. The PUCAI, Travis and Lindgren’s indices were strong predictors of failure of response to steroids[57]. In adult practice, the Travis criteria assessed on day 3 of steroid treatment indicate that a C-reactive protein > 45, and bowel action > 8 times per day, carry an 85% likelihood of subtotal colectomy during that admission[58]. The PUCAI has been promoted as a marker for failure of response to intravenous corticosteroids (day 3 > 45 points, and day 5 > 65-70 points) with a predictive accuracy of 85%-95%, allowing rapid introduction of second line medical therapies[57-59]. Early introduction of salvage medical therapies (cyclosporine, tacrolimus and infliximab) has reduced the emergency colectomy rate in ASC from 30%-70% to the current 10%-20%, with concomitant reduction in mortality[60]. Upper limits of normal colonic width in children with ASC should take age into consideration (4 cm < 11 years, and 6cm in older children)[57]. Absolute indicators for surgery in the setting of unresponsive ASC include perforation and significant haemorrhage. Otherwise the risks, benefits and potential psychological morbidity of colectomy should be considered alongside salvage medical therapies.

The surgical procedure of choice is colectomy and end ileostomy preserving the rectal stump[60,61]. The options for managing the rectal stump include formation of a mucous fistula, division at the sacral promontory, or subcutaneous placement beneath the laparotomy wound. The presence of a mucus fistula is associated with mucoid discharge which may be unacceptable[41]. Although subcutaneous placement increases wound infection rates, the rate of pelvic sepsis is decreased when compared with division at the rectosigmoid junction[62,63].

**LAPAROSCOPIC COLECTOMY AND POUCH ANAL ANASTOMOSIS**

The adult sector now has a large experience of the application of laparoscopic approaches to surgery for UC. A meta-analysis comparing open and laparoscopic subtotal colectomy identified a conversion rate of 5%. Significant benefit was shown for laparoscopic surgery in terms of wound infection, intra-abdominal abscess, and length of stay[64]. Laparoscopic IPAA is increasingly being performed in adult IBD centres. The application of these techniques to paediatric practice has been slower. Diamond *et al*[65] identified a 7% conversion rate in 42 children undergoing subtotal colectomy. Fraser *et al*[66] compared overall morbidity seen in 44 children undergoing different variations on a theme of total colectomy (including 27 children with UC) noting an overall major complication rate of 43% unaffected by laparoscopic or open approaches. Linden *et al*[67] compared open (39) and laparoscopic-assisted (68) IPAA, demonstrating a significantly reduced incidence of small bowel obstruction at 1 year follow up in the laparoscopic group. Sheth *et al*[68] compared open (37) and laparoscopic (45) IPAA (including 56 children with UC) demonstrating comparable outcomes and surgical morbidity. Flores *et al*[69] compared open and laparoscopic colectomy in 32 consecutive patients finding significantly shorter lengths of stay in the laparoscopic group[69].

**SURGICAL MANAGEMENT OF CD**

The life time risk of surgery for CD is approximately 80%[70]. Indications for surgical management of children with CD include failure of medical therapy, growth failure despite full medical therapy, associated extra-intestinal manifestations (especially eye and joint pathology), and complications of the disease (fistula, obstruction, perforation, abscess formation, and bleeding). Timely surgical intervention has been demonstrated to improve height velocities in patients refractory to medical therapy[71,72]. Location of disease also has a significant bearing on the decision to operate or to persevere with medical management, since a local resection with primary anastomosis is less psychologically debilitating than a major colonic resection and possible permanent stoma.

Using the Paris classification (modification of the Montreal classification)[73], applied to 582 children on the EUROKIDS registry, 16% had isolated terminal ileal disease (± limited caecal disease), 27% had isolated colonic involvement, ileocolonic disease was seen in 53%, and 4% had a disease distribution at presentation localised to the upper gastrointestinal tract[74]. A radiological study suggested an increased propensity for left sided colitis in children compared with adults[75].

The author’s surgical perspective is of clear phenotypic subtypes (relating to macroscopic disease location), which greatly simplify decision making. Thus ileocaecal distribution including contiguous disease to the just beyond hepatic flexure (watershed of ileocolic arterial blood supply), and left sided colitis, are distinct and usually mutually exclusive phenotypes. Isolated proximal small bowel disease is rare in paediatric practice[76].

***Resectional surgery***

Requirement for surgical resection ranges from 20%-29% at 3 years, and 34%-50% at 5 years from diagnosis in paediatric practice[77-79]. The fundamental surgical consideration is localization of the macroscopic disease in accordance with one of the “five golden rules” of Alexander-Williams and Haynes[80], which may be paraphrased thus; “resect only symptomatic macroscopic disease”. Children with ileocolic disease (with colonic involvement proximal to the mid-transverse colon) are readily managed by right hemicolectomy and primary anastomosis with low associated morbidity[76] (Figure 3).

Debate continues regarding the management of colonic disease distal to the transverse colon, and whether this might break the golden rule of surgical conservatism. The phenotype associated with left sided colitis in childhood has been shown to relapse early following segmental resection[81], or develop significant complications from anastomotic failure after segmental resection[76]. An adult meta-analysis (448 patients) suggested that segmental resection was not associated with increased overall recurrence rates, complications, or need for a permanent stoma, but that time to recurrence was longer by 4.4 years in the subtotal resection group[82]. However, segmental resection for left sided colitis continues to be advocated by some surgeons, citing preservation of anorectal function and decreased post-operative symptoms[83]. Another study advocated segmental resection over subtotal colectomy and IRA, based on favourable clinical recurrence rates, reoperation rates and risk of permanent stoma requirement. Risk factors for recurrence/reoperation included both perianal Crohn’s disease and colocolic anastomosis, which implies that ileocolic anastomoses were included in the evaluation and thus that cases of right sided colitis were included in the evaluation[84]! A possible explanation for the difference between the paediatric and adult experience is that subtotal colectomy with end ileostomy was favoured in children compared to IRA in adults. Defunctioning the rectum in Crohn’s colitis is potentially therapeutic for associated CD within the retained rectum[85], but might predispose to later disuse proctitis. Prospects for restoration of continuity are limited, and the adolescent needs to know that the stoma may be permanent and that half of all patients will eventually come to proctectomy[86].

***Disease recurrence***

Recurrence following surgery in paediatric Crohn’s disease has received little attention in the paediatric surgical literature since transition to adult care has usually taken place before repeat surgery is required. A small paediatric series comprising 82 children undergoing surgery for CD concluded that early recurrence was associated with extensive colonic disease, long duration of symptoms (> 1 year) before surgery, and failure of medical therapy as underlying reason for surgery[72]. Another paediatric series found significantly earlier recurrence in children with colonic rather than ileocaecal disease. The same report also showed that high PCDAI scores were correlated with a shorter remission periods[87]. In a study of 1936 adult patients, surgical re-intervention was required in 25%-35% of all patients at 5 years and 40%-70% at 15 years[88]. The only patient-related factor consistently associated with early recurrence is smoking[89]. Studies analysing the influence of disease location on recurrence have shown no particular correlation, but the perforating/fistulating phenotype increases both clinical and surgical recurrence[89]. Studies looking at the influence of resection margins on disease recurrence have provided conflicting results. Most surgeons would advocate conservative resection to achieve margins free of macroscopic disease, with support from a randomized controlled trial[90]. There remains controversy surrounding the effect of anastomotic configuration (side to side versus end to end) on disease recurrence. The most recent meta-analysis suggested that side to side anastomosis was associated with reduced rate of recurrence[91], while an earlier meta-analysis and a randomized controlled trial failed to demonstrate any difference[92,93]. Recommendations on postoperative drug prophylaxis to prevent recurrence are lacking[89], but given the efficacy of thiopurine therapy in maintaining remission[94], there is a broad consensus in favour of maintaining this treatment in children after resectional surgery.

***Anastomotic Technique***

The meta-analysis conducted by Simillis *et al*[92] concluded that side to side configuration was associated with fewer postoperative complications. The Cochrane review of ileocolic anastomoses concluded that stapled anastomosis were associated with fewer anastomotic leaks than handsewn, although subgroup analysis did not achieve significance in non-cancer patients[95]. Individual large volume cohort studies comparing stapled and hand sewn anastomoses in the treatment of CD have suggested a significant reduction in both anastomotic leak rate[96], and requirement for reoperation for anastomotic recurrence[97]. Lack of cross fertilization between adult and paediatric practice has undoubtedly been a factor in late adoption of stapling approaches to various anastomoses in paediatric IBD practice. Appropriate mentoring is essential in the adoption of any new technique, since use of an unfamiliar technique is associated with a higher incidence of complications including anastomotic failure[98].

***Pre-operative optimisation***

Risk factors associated with postoperative sepsis include poor nutritional status (where albumin < 30 g/L is a useful proxy), presence of abscess or fistula, preoperative steroids[99,100], and recurrent clinical exacerbations of CD[100]. Since the risk of a septic complication is additive with each of these risk factors[99], foreknowledge should prompt consideration of a temporary stoma rather than an anastomosis[100]. These considerations have fuelled the debate on preoperative optimization in patients with CD. To date there is little strong evidence supporting delaying surgery to allow for a period of pre-operative hyperalimentation by either enteral or parenteral routes[101]. However medical management of sepsis and percutaneous drainage of intra-abdominal abscesses may reduce post-operative septic complications[101].

***Strictureplasty***

Repeated resectional surgery in CD is clearly associated with a risk of short bowel syndrome in adulthood. For this reason strictureplasty has become an established surgical approach with proven efficacy and safety in adult practice[102]. A meta-analysis (1112 patients) identified septic complications in 4% and a 5 year recurrence rate of 28%[103]. As has been seen elsewhere paediatric surgeons have been slow to adopt strictureplasty into their operative repertoire. A comparative study of strictureplasty (19), resection (13), and combined (8) procedures in children demonstrated that strictureplasty was associated with a significantly earlier recurrence rate[104]. However another paediatric group have successfully used strictureplasty in long segment stenosis without complication and with good symptom control[105].

***Balloon dilatation for Crohn’s strictures.***

The evidence for balloon dilatation of strictures in Crohn’s Disease is limited to the adult literature only. One third of patients diagnosed with Crohn’s disease develop strictures within 10 years of diagnosis[106]. Dilatation is usually attempted to a diameter of 18-25 mm in gradual increments[107]. Complications include bleeding and perforation. Short term success rates are 86%-94%[107,108], which may be enhanced when used in conjunction with oral corticosteroids[109], or intralesional steroid injection[107]. Intervention-free success rates decline over time, with relapse rates quoted as 46% after a mean of 32 months. However one third of patients require no further treatment ten years after their first dilatation[107].

**SPECIAL SITES**

***Perianal Crohn’s disease***

The management of PACD continues to pose a significant challenge to both gastroenterologist and surgeon, despite significant advances in understanding of the epidemiology and natural history, occurring alongside the development of new treatment modalities. As in other areas of paediatric IBD practice, there is a distinct lack of good quality evidence on which to base therapeutic strategy, and reliance is therefore placed on extrapolation from the adult literature, and from expert consensus.

The incidence of symptomatic PACD at presentation in a cohort of 145 children with CD in the Northwest of England was 25 (17%). The majority (80%) required some form of surgical intervention for their PACD. Paediatric studies suggest a wide range of incidence from 15% at initial presentation[110], to 62% over the course of their disease[111]. This wide disparity may reflect a degree of inattention (from either patient or doctor) to mild PACD in the setting of more debilitating disease at other sites, or reporting bias depending on medical or surgical authorship. PACD represents a spectrum of pathologies which can follow a relatively benign course, through to a locally aggressive process relentlessly progressing towards proctectomy. The presence of PACD has been associated with young age at presentation, ileal disease distribution and defective expression of neutrophil cytosolic factor (NCF4), again linking pathogenesis with defective invasive bacterial defensive mechanisms[112].

The most commonly used descriptive assessment of PACD is the Cardiff classification which reflects the severity of three components of the disease spectrum; ulceration, abscess/fistula and anal stricture. Additional information is given concerning associated anal disease (A), proximal intestinal Crohn’s disease location (P), and inflammatory activity in the perianal disease (D)[113]. The Parks classification can only be applied to fistulating PACD and is a precise anatomical description of the fistula track in relation to the sphincter complex (superficial, intersphincteric, transphincteric, suprasphincteric and extrasphincteric), remembering that there may be multiple separate fistulae to describe in this way[114]. More recently an attempt has been made to simplify the classification of fistulae into simple and complex disease based on anatomy of the fistula, and the presence or absence of abscesses, strictures, and of significant rectal disease[115]. The perianal Crohn’s disease activity index, abbreviated PACDAI for the purposes of this article to distinguish it from the paediatric Crohn’s disease activity index (PCDAI), enables quantitative assessment of treatment efficacy[116], and has largely superseded the earlier classification of Irvine[117]. The PACDAI has no quality of life component, unlike Irvine’s score in which two of the five categories reflect interference with social and sexual activity. Both scoring systems were derived for adult patients, but since the former has as its focus the pathology of PACD, it can be applied to paediatric practice. As with many medical scoring systems, the PACDAI assigns a weighted numeric value to each component of the clinical picture assuming that the derived cumulative total has a value in quantifying disease severity. The result is a cumbersome tool whose value is less in the overall score and more in the precise description of each component of PACD. The authors consider the differentiation of PACD into ulcerating, fistulating and stenosing disease (after Cardiff) to have prognostic significance in terms of the likelihood of proctectomy. Our experience is that ulcerating PACD is often difficult to control, and if progressive can result in the need for proctectomy. Others, like us, have also concluded that stenotic PACD is associated with an unfavourable prognosis[118].

Effective management of PACD requires close collaboration between gastroenterologist and surgeon with appropriate use of imaging techniques. Three essential principles guide management; the prompt identification and drainage of any septic focus, conservative surgery, and appropriate medical therapy. The locally destructive effects of abscess formation and often significant pain both mandate early surgical drainage. The impaired wound healing commonly seen in patients with Crohn’s disease, should make a surgeon think twice about embarking on extensive perianal surgery. Fistulotomy may be undertaken in simple PACD with extra-sphincteric or short low inter-sphicteric fistula tracks in medically well-controlled disease and in the absence of significant rectal disease. However most surgeons favour the use of non-cutting setons to control septic complications from fistulae, especially in complex PACD. Setons are extremely well tolerated and, after drainage of pus, represent the principal adjunctive surgical contribution to medical management. Antibiotics (metronidazole and ciprofloxacillin) are effective in controlling acute exacerbations of PACD[119], and together with maintenance immunosuppression using thiopurines (azathioprine or mercaptopurine) comprise the first line of medical management. Steroids have no place in the treatment of PACD[120].

Since its introduction to the medical armamentarium against Crohn’s disease in 1999[121], the chimeric anti-TNF monoclonal antibody infliximab has provided an effective second line of medical management in recalcitrant Crohn’s perianal fistulae. Paediatric studies have confirmed its efficacy in the management of PACD[122,123]. Before embarking upon such biological therapy, the exclusion of occult sepsis should be mandatory and pelvic MRI should be undertaken, both for this purpose, and to document the extent of PACD at the start of therapy[124]. Early optimism associated with infliximab has persisted into more recent paediatric reports of control of fistulating disease in 76% at 1 year[123], and 56% at 2 years[125]. This experience has translated into some advocating infliximab as first line therapy in children with fistulating PACD rather than the “step up” approach outlined above[126]. Whilst expert opinion is tending to favour combined use of setons and infliximab in the treatment of complex Crohn’s perianal fistulae[127], there is no consensus regarding timing of removal of the seton and subsequent duration of biological therapy, although there is general agreement that full therapy should continue for a year[94]. Some authors are reluctant to recommend discontinuation of infliximab therapy because of the high relapse rate of fistulating PACD[128]. Similarly, others prefer to emphasize tolerability and efficacy of a long-term indwelling seton in control of complex PACD[129].

Appropriate evaluation of PACD should include recent anatomical localization of active disease burden by endoscopy and contrast-, or MR-enteroclysis. Pelvic MRI should be undertaken prior to EUA and rectosigmoidoscopy, for reasons identified above and also as a guide to informed surgical consent. Abscesses pointing to the perianal skin should be drained externally. Pelvic abscesses can be effectively drained using the trans-rectal route in the hope of avoiding formation of an iatrogenic extra-sphincteric fistula. Horse-shoe abscesses represent a particular challenge and may be drained *via* a trans-anorectal route. If control cannot be achieved by effective internal drainage and intensive medical management including antibiotics, thiopurine immunosuppressive maintenance, and infliximab, then a defunctioning stoma accompanied by laying open of the post anal space together with seton insertion will be required to achieve control of sepsis and hopefully avoid proctectomy. More complex fistulating disease involving the vagina or urinary tract is rarely seen in paediatric practice, and will usually require a defunctioning stoma in the first instance. In this circumstance fistula eradication is only going to be successful if there is no significant inflammatory involvement of the anorectum apart from that associated with the fistula itself. In the absence of significant proctitis, rectal mucosal advancement flaps[130], and interposition techniques such as graciloplasty[131] have all been employed with limited success.

A defunctioning stoma may provide significant temporary relief in advanced ulcerating, fistulating or stenotic PACD (usually seen in advanced Crohn’s proctitis), but healing of perianal disease, if it occurs to any meaningful extent, is usually reversed on restoration of continuity. This approach often only delays eventual proctectomy, which is required within 8 years in 50% of patients with locally aggressive PACD[132].

Proctectomy is not the end of the surgical challenge in this situation, since healing of the resultant perineal wound is often the exception rather than the rule. The use of topical negative pressure dressings to control sepsis, and, where necessary, delayed application of transposition muscle/myocutaneous flaps, can result in an acceptable cosmetic result.

In recent years novel local treatments directed at the fistula track in PACD have included the use of the CO2 laser[133], fibrin glues[134], and fistula plugs[135]. Local injection of infliximab into the fistula track[136], and the delivery of adipose tissue-derived stem cells either by direct injection[137] or by incorporating them into fistula plugs are current research developments that are showing some promise.

***Upper Gastrointestinal Crohn’s Disease***

Upper GI endoscopy is mandatory in the investigation of CD since inflammatory changes have been demonstrated in up to 40% of children[138]. The incidence of gastroduodenal CD was only 10% in a group of 196 children in whom gastroduodenoscopy was solely performed in children with suggestive symptoms. Most cases with upper GI involvement are therefore asymptomatic with respect to the gastroduodenal inflammatory changes[139]. Endoscopic and histological findings are variable and often non-specific[140]. Medical treatment is rarely directed at the gastroduodenal disease alone since symptomatic disease is usually present distally. If treatment is deemed necessary then proton-pump inhibitors should be included with standard first line treatment[140]. There is no body of literature describing surgical intervention in childhood. The benign outlook in children is not reflected in the adult literature which probably reflects the fact that the huge adult caseload allows rare cases of clinically significant macroscopic gastroduodenal disease to come to the fore. Yamamoto *et al*[141] describe 54 patients with gastroduodenal disease in whom 33 required surgery mainly for gastric outlet obstruction (16 bypass, 10 strictureplasty and 4 gastrectomy). One third required re-operation for recurrent obstruction or stomal ulceration.

**NEW DEVELOPMENTS IN SURGERY IN CHILDREN WITH IBD**

The low case volume in paediatric IBD surgery has led to this subspecialty service being late adapters of technological and other advances coming out of adult colorectal practice as has been argued frequently in this article. The benefits of collaborative practice may seem self-evident, but take considerable effort to accrue, given the artificial separation of adult and paediatric medicine. In concluding this review we consider the potential benefits to paediatric practice of accelerated recovery programmes which are now commonplace in adult units, and mechanisms that ensure continuity of care as adolescents with IBD reach the interface between paediatric and adult services.

**ENHANCED RECOVERY AFTER SURGERY**

The recent widespread adoption of fast-track protocols in adult colorectal surgery has led to reduction in length of hospital stay with concomitant cost-reduction[142-145]. Enhanced recovery after surgery (ERAS) protocols focus on drawing together preoperative, intraoperative and postoperative considerations, which might enhance recovery, into a cohesive care package designed to effect significant gains by delivering multiple small increments of improved care. Studies of ERAS application in major colonic resections predominantly for inflammatory bowel disease have demonstrated either comparable[146], or reduced morbidity[147]. These benefits remain to be confirmed in children, but a comparative study of “conventional management” of children undergoing resectional surgery for inflammatory bowel disease, and of young adults (less than 25 years old) undergoing matched procedures according to an ERAS protocol, has demonstrated a significant reduction in hospital stay in the ERAS group without increase in morbidity[148]. This matched cohort study lacks the power of a RCT, but strongly suggests that the gains obtained from accelerated recovery programmes can be translated into paediatric IBD surgical practice.

Laparoscopy is considered to be an area in which gains might be achieved in earlier recovery, reduced pain and improved cosmesis, and is an integral part of many ERAS protocols. Demonstrating significant benefit for laparoscopy in any area other than cosmesis is highly controversial. This however does not detract from its potential value within a highly structured care package.

**TRANSITIONAL CARE**

The unique problems that arise in children with IBD, and the models of delivery of care in children’s services probably both conspire to delay referral into the adult sector. However, a recent United Kingdom study of paediatric IBD services suggested that transitional care arrangements were well established in most tertiary centres, and indeed that shared care with adult surgeons was a feature of practice, especially in relation to ileoanal pouch surgery. This is probably explained both by the lack of exposure to IBD surgery in the training programmes of United Kingdom paediatric surgeons, and by the small case load even in the larger centres[15].

The fact that most children requiring colectomy and IPAA for UC are approaching the age at which transition into adult care is feasible, strengthens the argument for adult surgical involvement, since the ethics of undertaking surgery with a high complication rate and then transferring responsibility for follow up within a short time frame is certainly open to question. Furthermore case volume considerations, and the allocation of research funding and scarce health care resources, maximise the options available for the young patient with IBD to access the newest treatment when shared care is available.

Consensus guidelines issued jointly by the European Crohn’s and Colitis Organization and the ESPGHAN[149], state that every adolescent should be included in a transitional care programme which is adapted to fit local paediatric and adult health care models, and that within the paediatric setting adolescents should be encouraged to take increasing responsibility for their treatment and visit the clinic at least once without their parents. Endoscopic interventions in children with IBD are performed under general anaesthesia and are largely diagnostic. Adult endoscopy is performed almost exclusively under sedation and is performed more frequently given the increasing emphasis on surveillance with duration of disease. Other details of care which enhance the perception that paediatric health care delivery is more child-friendly, include the emphasis on nutrition, growth, puberty and psychological well-being, including integrating health care into the educational needs of the child. These factors are therefore potential barriers to timely transition, which need to be overcome to ensure that each adolescent can access the full range of treatment options.

There are no research studies with confirm the suggested benefits of well-organized transition services in IBD[150]. However it is likely that the perceived benefits of structured transition programmes seen in other chronic paediatric conditions will translate into the setting of adolescent IBD[151].

**REFERENCES**

1 **Sawczenko A**, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, Lynn R. Prospective survey of childhood inflammatory bowel disease in the British Isles. *Lancet* 2001; **357**: 1093-1094 [PMID: 11297962 DOI: 10.1016/S0140-6736(00)04309-9]

2 **Sawczenko A**, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. *Arch Dis Child* 2003; **88**: 995-1000 [PMID: 14612366 DOI: 10.1136/adc.88.11.995]

3 **Heyman MB**, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, Winter HS, Fain P, King C, Smith T, El-Serag HB. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. *J Pediatr* 2005; **146**: 35-40 [PMID: 15644819 DOI: 10.1016/j.jpeds.2004.08.043]

4 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

5 **Ogura Y**, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. *J Biol Chem* 2001; **276**: 4812-4818 [PMID: 11087742 DOI: 10.1074/jbc.M008072200]

6 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

7 **Shaw MH**, Kamada N, Warner N, Kim YG, Nuñez G. The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation. *Trends Immunol* 2011; **32**: 73-79 [PMID: 21251876 DOI: 10.1016/j.it.2010.12.007]

8 **Spehlmann ME**, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. *Inflamm Bowel Dis* 2008; **14**: 968-976 [PMID: 18253950 DOI: 10.1002/ibd.20380]

9 **Büning C**, Genschel J, Bühner S, Krüger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. *Aliment Pharmacol Ther* 2004; **19**: 1073-1078 [PMID: 15142196 DOI: 10.1111/j.1365-2036.2004.01967.x]

10 **Angelberger S**, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. *Am J Gastroenterol* 2008; **103**: 1197-1202 [PMID: 18371140 DOI: 10.1111/j.1572-0241.2007.01741.x]

11 **Vermeire S**, Pierik M, Hlavaty T, Claessens G, van Schuerbeeck N, Joossens S, Ferrante M, Henckaerts L, Bueno de Mesquita M, Vlietinck R, Rutgeerts P. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. *Gastroenterology* 2005; **129**: 1845-1853 [PMID: 16344053 DOI: 10.1053/j.gastro.2005.10.006]

12 **Latiano A**, Palmieri O, Cucchiara S, Castro M, D'Incà R, Guariso G, Dallapiccola B, Valvano MR, Latiano T, Andriulli A, Annese V. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. *Am J Gastroenterol* 2009; **104**: 110-116 [PMID: 19098858 DOI: 10.1038/ajg.2008.3]

13 **Armuzzi A**, Ahmad T, Ling KL, de Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. *Gut* 2003; **52**: 1133-1139 [PMID: 12865271 DOI: 10.1136/gut.52.8.1133]

14 UK IBD Working Group on behalf of the British Society of PaediatricGastroenterology Hepatology and Nutrition (BSPGHAN).Guidelines for the Management of Inflammatory Bowel Disease (IBD)in Children in the United Kingdom. Available from: URL: https://www.bspghan.org.uk/documents/IBDGuidelines.pdf

15 **Smith NP**, Ba'ath ME, Perry D, Morgan LE, Lamont GL, Baillie CT. BAPS UK inflammatory bowel disease surgical practice survey. *J Pediatr Surg* 2007; **42**: 296-299 [PMID: 17270538 DOI: 10.1016/j.jpedsurg.2006.10.002]

16 **IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.** Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. *J Pediatr Gastroenterol Nutr* 2005; **41**: 1-7 [PMID: 15990620]

17 **Hyams JS**, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT. Development and validation of a pediatric Crohn's disease activity index. *J Pediatr Gastroenterol Nutr* 1991; **12**: 439-447 [PMID: 1678008]

18 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19** Suppl A: 5A-36A [PMID: 16151544]

19 **Turner D**, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* 2007; **133**: 423-432 [PMID: 17681163 DOI: 10.1053/j.gastro.2007.05.029]

20 **Van Limbergen J**, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology* 2008; **135**: 1114-1122 [PMID: 18725221 DOI: 10.1053/j.gastro.2008.06.081]

21 **Tomomasa T,** Tajiri H, Kagimoto S, Shimizu T, Yoden A, Ushijima K, Uchida K,

Kaneko H, Abukawa D, Konno M, Maisawa S, Kohsaka T, Kobayashi A; Japanese Study Group for Pediatric Ulcerative Colitis. Leukocytapheresis in pediatric patients with ulcerative colitis.  *J Pediatr Gastroenterol Nutr* 2011; **53**: 34-39 [PMID: 21694533 DOI: 10.1097/MPG.0b013e31821058bc]

22 **Baldassano R**, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. *Am J Gastroenterol* 2003; **98**: 833-838 [PMID: 12738464 DOI: 10.1111/j.1572-0241.2003.07343.x]

23 **Hyams J**, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. *Gastroenterology* 2007; **132**: 863-73; quiz 1165-6 [PMID: 17324398 DOI: 10.1053/j.gastro.2006.12.003]

24 **Condino G**, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. *Dig Liver Dis* 2013; **45**: 258-262 [PMID: 23195667 DOI: 10.1016/j.dld.2012.10.009]

25 **Gasparetto M**, Corradin S, Vallortigara F, Cananzi M, Guariso G. Infliximab and pediatric stricturing Crohn's disease: a possible alternative to surgery? Experience of seven cases. *Acta Gastroenterol Belg* 2012; **75**: 58-60 [PMID: 22567750]

26 **Ananthakrishnan AN**, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. *J Gastrointest Surg* 2011; **15**: 267-276 [PMID: 21108015 DOI: 10.1007/s11605-010-1396-3]

27 **Goudet P**, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. *Dig Surg* 2001; **18**: 51-55 [PMID: 11244260 DOI: 10.1159/000050097]

28 **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]

29 **Peneau A**, Savoye G, Turck D, Dauchet L, Fumery M, Salleron J, Lerebours E, Ligier K, Vasseur F, Dupas JL, Mouterde O, Spyckerelle C, Djeddi D, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. *Am J Gastroenterol* 2013; **108**: 1647-1653 [PMID: 23939626 DOI: 10.1038/ajg.2013.242]

30 **de Ridder L**, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, Spray C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Cucchiara S, Veres G, Ruemmele FM, Hojsak I, Kolho KL, Davies IH, Aloi M, Lionetti P, Veereman-Wauters G, Braegger CP, Trindade E, Wewer AV, Hauer A, Levine A. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. *Inflamm Bowel Dis* 2014; **20**: 291-300 [PMID: 24374875 DOI: 10.1097/01.MIB.0000439066.69340.3c]

31 **Malaty HM**, Abraham BP, Mehta S, Garnett EA, Ferry GD. The natural history of ulcerative colitis in a pediatric population: a follow-up population-based cohort study. *Clin Exp Gastroenterol* 2013; **6**: 77-83 [PMID: 23825926 DOI: 10.2147/CEG.S40259]

32 **Hyams JS**, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. *J Pediatr* 1996; **129**: 81-88 [PMID: 8757566]

33 **Gower-Rousseau C**, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas JL, Savoye G, Baldé M, Marti R, Lerebours E, Cortot A, Salomez JL, Turck D, Colombel JF. The natural history of pediatric ulcerative colitis: a population-based cohort study. *Am J Gastroenterol* 2009; **104**: 2080-2088 [PMID: 19436273 DOI: 10.1038/ajg.2009.177]

34 **Parks AG**, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. *Br Med J* 1978; **2**: 85-88 [PMID: 667572]

35 **Coran AG**. A personal experience with 100 consecutive total colectomies and straight ileoanal endorectal pull-throughs for benign disease of the colon and rectum in children and adults. *Ann Surg* 1990; **212**: 242-27; discussion 242-27; [PMID: 2396880]

36 **Cohen JL**, Strong SA, Hyman NH, Buie WD, Dunn GD, Ko CY, Fleshner PR, Stahl TJ, Kim DG, Bastawrous AL, Perry WB, Cataldo PA, Rafferty JF, Ellis CN, Rakinic J, Gregorcyk S, Shellito PC, Kilkenny JW, Ternent CA, Koltun W, Tjandra JJ, Orsay CP, Whiteford MH, Penzer JR. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum* 2005; **48**: 1997-2009 [PMID: 16258712]

37 **Brown J**, Meyer F, Klapproth JM. Aspects in the interdisciplinary decision-making for surgical intervention in ulcerative colitis and its complications. *Z Gastroenterol* 2012; **50**: 468-474 [PMID: 22581702 DOI: 10.1055/s-0031-1299467]

38 **Hwang JM**, Varma MG. Surgery for inflammatory bowel disease. *World J Gastroenterol* 2008; **14**: 2678-2690 [PMID: 18461653 DOI: 10.3748/wjg.14.2678]

39 **Tilney HS**, Constantinides V, Ioannides AS, Tekkis PP, Darzi AW, Haddad MJ. Pouch-anal anastomosis vs straight ileoanal anastomosis in pediatric patients: a meta-analysis. *J Pediatr Surg* 2006; **41**: 1799-1808 [PMID: 17101347 DOI: 10.1016/j.jpedsurg.2006.06.005]

40 **Remzi FH**, Fazio VW, Gorgun E, Ooi BS, Hammel J, Preen M, Church JM, Madbouly K, Lavery IC. The outcome after restorative proctocolectomy with or without defunctioning ileostomy. *Dis Colon Rectum* 2006; **49**: 470-477 [PMID: 16518581]

41 **Böhm G**, O'Dwyer ST. The fate of the rectal stump after subtotal colectomy for ulcerative colitis. *Int J Colorectal Dis* 2007; **22**: 277-282 [PMID: 16586076]

42 **Lovegrove RE**, Constantinides VA, Heriot AG, Athanasiou T, Darzi A, Remzi FH, Nicholls RJ, Fazio VW, Tekkis PP. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. *Ann Surg* 2006; **244**: 18-26 [PMID: 16794385]

43 **Seetharamaiah R**, West BT, Ignash SJ, Pakarinen MP, Koivusalo A, Rintala RJ, Liu DC, Spencer AU, Skipton K, Geiger JD, Hirschl RB, Coran AG, Teitelbaum DH. Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. *J Pediatr Surg* 2009; **44**: 1410-1417 [PMID: 19573671 DOI: 10.1016/j.jpedsurg.2009.01.006]

44 **Rintala RJ**, Lindahl H. Restorative proctocolectomy for ulcerative colitis in children--is the J-pouch better than straight pull-through? *J Pediatr Surg* 1996; **31**: 530-533 [PMID: 8801306 DOI: 10.1016/S0022-3468(96)90489-3]

45 **Browning SM**, Nivatvongs S. Intraoperative abandonment of ileal pouch to anal anastomosis--the Mayo Clinic experience. *J Am Coll Surg* 1998; **186**: 441-45; discussion 441-45; [PMID: 9544959 DOI: 10.1016/S1072-7515(98)00056-8]

46 **Alexander F**, Sarigol S, DiFiore J, Stallion A, Cotman K, Clark H, Lydzinski B, Fazio V. Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. *J Pediatr Surg* 2003; **38**: 78-82 [PMID: 12592624 DOI: 10.1053/jpsu.2003.50015]

47 **Koivusalo A,** Pakarinen MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. *J Pediatr Surg* 2007; **42**: 290-295 [PMID: 17270537 DOI: 10.1016/j.jpedsurg.2006.10.001]

48 **Patton D**, Gupta N, Wojcicki JM, Garnett EA, Nobuhara K, Heyman MB. Postoperative outcome of colectomy for pediatric patients with ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2010; **51**: 151-154 [PMID: 20410838 DOI: 10.1097/MPG.0b013e3181c99290]

49 **Tulchinsky H**, Cohen CR, Nicholls RJ. Salvage surgery after restorative proctocolectomy. *Br J Surg* 2003; **90**: 909-921 [PMID: 12905542 DOI: 10.1002/bjs.4278]

50 **da Luz Moreira A**, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. *Br J Surg* 2010; **97**: 65-69 [PMID: 20013930 DOI: 10.1002/bjs.6809]

51 **Mortier PE**, Gambiez L, Karoui M, Cortot A, Paris JC, Quandalle P, Colombel JF. Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. *Gastroenterol Clin Biol* 2006; **30**: 594-597 [PMID: 16733384]

52 **Leijonmarck CE**, Löfberg R, Ost A, Hellers G. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. *Dis Colon Rectum* 1990; **33**: 195-200 [PMID: 2311462]

53 **Waljee A**, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. *Gut* 2006; **55**: 1575-1580 [PMID: 16772310]

54 **Cornish JA**, Tan E, Teare J, Teoh TG, Rai R, Darzi AW, Paraskevas P, Clark SK, Tekkis PP. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. *Dis Colon Rectum* 2007; **50**: 1128-1138 [PMID: 17588223]

55 **Koivusalo A**, Pakarinen MP, Natunen J, Ashorn M, Rintala RJ, Sipponen T, Kolho KL. Sexual functions in adulthood after restorative proctocolectomy for paediatric onset ulcerative colitis. *Pediatr Surg Int* 2009; **25**: 881-884 [PMID: 19669154 DOI: 10.1007/s00383-009-2437-4]

56 **Dalal DH**, Patton D, Wojcicki JM, Clark AL, Garnett EA, Heyman MB. Quality of life in patients postcolectomy for pediatric-onset ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2012; **55**: 425-428 [PMID: 22437468]

57 **Turner D**, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, McLernon RA, Walters TD, Swales J, Steinhart AH, Griffiths AM. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. *Gut* 2008; **57**: 331-338 [PMID: 17981888]

58 **Travis SP**, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. *Gut* 1996; **38**: 905-910 [PMID: 8984031]

59 **Turner D**, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. *Inflamm Bowel Dis* 2011; **17**: 440-449 [PMID: 20645317 DOI: 10.1002/ibd.21383]

60 **Dayan B**, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. *World J Gastroenterol* 2012; **18**: 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833]

61 **Hawley PR**. Emergency surgery for ulcerative colitis. *World J Surg* 1988; **12**: 169-173 [PMID: 3394341]

62 **Trickett JP**, Tilney HS, Gudgeon AM, Mellor SG, Edwards DP. Management of the rectal stump after emergency sub-total colectomy: which surgical option is associated with the lowest morbidity? *Colorectal Dis* 2005; **7**: 519-522 [PMID: 16108892 DOI: 10.1111/j.1463-1318.2005.00875.x]

63 **Ng RL**, Davies AH, Grace RH, Mortensen NJ. Subcutaneous rectal stump closure after emergency subtotal colectomy. *Br J Surg* 1992; **79**: 701-703 [PMID: 1643491]

64 **Bartels SA**, Gardenbroek TJ, Ubbink DT, Buskens CJ, Tanis PJ, Bemelman WA. Systematic review and meta-analysis of laparoscopic versus open colectomy with end ileostomy for non-toxic colitis. *Br J Surg* 2013; **100**: 726-733 [PMID: 23355043 DOI: 10.1002/bjs.9061]

65 **Diamond IR**, Gerstle JT, Kim PC, Langer JC. Outcomes after laparoscopic surgery in children with inflammatory bowel disease. *Surg Endosc* 2010; **24**: 2796-2802 [PMID: 20396907 DOI: 10.1007/s00464-010-1050-x]

66 **Fraser JD**, Garey CL, Laituri CA, Sharp RJ, Ostlie DJ, St Peter SD. Outcomes of laparoscopic and open total colectomy in the pediatric population. *J Laparoendosc Adv Surg Tech A* 2010; **20**: 659-660 [PMID: 20822419 DOI: 10.1089/lap.2010.0086]

67 **Linden BC**, Bairdain S, Zurakowski D, Shamberger RC, Lillehei CW. Comparison of laparoscopic-assisted and open total proctocolectomy and ileal pouch anal anastomosis in children and adolescents. *J Pediatr Surg* 2013; **48**: 1546-1550 [PMID: 23895970 DOI: 10.1016/j.jpedsurg.2012.08.031]

68 **Sheth J**, Jaffray B. A comparison of laparoscopic and open restorative proctocolectomy in children. *J Pediatr Surg* 2014; **49**: 262-24; discussion 264 [PMID: 24528962 DOI: 10.1016/j.jpedsurg.2013.11.034]

69 **Flores P**, Bailez MM, Cuenca E, Fraire C. Comparative analysis between laparoscopic (UCL) and open (UCO) technique for the treatment of ulcerative colitis in pediatric patients. *Pediatr Surg Int* 2010; **26**: 907-911 [PMID: 20632014 DOI: 10.1007/s00383-010-2669-3]

70 **Caprilli R**, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. *Gut* 2006; **55** Suppl 1: i36-i58 [PMID: 16481630 DOI: 10.1136/gut.2005.081950c]

71 **Singh Ranger G**, Lamparelli MJ, Aldridge A, Chong SK, Mitton SG, Albanese A, Kumar D. Surgery results in significant improvement in growth in children with Crohn's disease refractory to medical therapy. *Pediatr Surg Int* 2006; **22**: 347-352 [PMID: 16518590]

72 **Griffiths AM**, Wesson DE, Shandling B, Corey M, Sherman PM. Factors influencing postoperative recurrence of Crohn's disease in childhood. *Gut* 1991; **32**: 491-495 [PMID: 2040470]

73 **Levine A**, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011; **17**: 1314-1321 [PMID: 21560194 DOI: 10.1002/ibd.21493]

74 **de Bie CI**, Paerregaard A, Kolacek S, Ruemmele FM, Koletzko S, Fell JM, Escher JC. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. *Inflamm Bowel Dis* 2013; **19**: 378-385 [PMID: 22573581 DOI: 10.1002/ibd.23008]

75 **Maccioni F**, Viola F, Carrozzo F, Di Nardo G, Pino AR, Staltari I, Al Ansari N, Vestri A, Signore A, Marini M, Cucchiara S. Differences in the location and activity of intestinal Crohn's disease lesions between adult and paediatric patients detected with MRI. *Eur Radiol* 2012; **22**: 2465-2477 [PMID: 22926159 DOI: 10.1007/s00330-012-2482-6]

76 **Ba'ath ME**, Mahmalat MW, Kapur P, Smith NP, Dalzell AM, Casson DH, Lamont GL, Baillie CT. Surgical management of inflammatory bowel disease. *Arch Dis Child* 2007; **92**: 312-316 [PMID: 16670116]

77 **Vernier-Massouille G**, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. *Gastroenterology* 2008; **135**: 1106-1113 [PMID: 18692056 DOI: 10.1053/j.gastro.2008.06.079]

78 **Patel HI**, Leichtner AM, Colodny AH, Shamberger RC. Surgery for Crohn's disease in infants and children. *J Pediatr Surg* 1997; **32**: 1063-107; discussion 1063-107; [PMID: 9247235 DOI: 10.1016/S0022-3468(97)90400-0]

79 **Sedgwick DM**, Barton JR, Hamer-Hodges DW, Nixon SJ, Ferguson A. Population-based study of surgery in juvenile onset Crohn's disease. *Br J Surg* 1991; **78**: 171-175 [PMID: 2015463]

80 **Alexander-Williams J**, Haynes IG. Up-to-date management of small-bowel Crohn's disease. *Adv Surg* 1987; **20**: 245-264 [PMID: 3535442]

81 **Davies G**, Evans CM, Shand WS, Walker-Smith JA. Surgery for Crohn's disease in childhood: influence of site of disease and operative procedure on outcome. *Br J Surg* 1990; **77**: 891-894 [PMID: 2393812]

82 **Tekkis PP**, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR, Nicholls RJ, Darzi AW. A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta-analysis. *Colorectal Dis* 2006; **8**: 82-90 [PMID: 16412066 DOI: 10.1111/j.1463-1318.2005.00903.x]

83 **Andersson P**, Olaison G, Hallböök O, Sjödahl R. Segmental resection or subtotal colectomy in Crohn's colitis? *Dis Colon Rectum* 2002; **45**: 47-53 [PMID: 11786764]

84 **Makowiec F**, Paczulla D, Schmidtke C, Starlinger M. Long-term follow-up after resectional surgery in patients with Crohn's disease involving the colon. *Z Gastroenterol* 1998; **36**: 619-624 [PMID: 9773479]

85 **Winslet MC**, Andrews H, Allan RN, Keighley MR. Fecal diversion in the management of Crohn's disease of the colon. *Dis Colon Rectum* 1993; **36**: 757-762 [PMID: 8348866]

86 **Yamamoto T**, Keighley MR. Long-term outcome of total colectomy and ileostomy for Crohn disease. *Scand J Gastroenterol* 1999; **34**: 280-286 [PMID: 10232873]

87 **Baldassano RN**, Han PD, Jeshion WC, Berlin JA, Piccoli DA, Lautenbach E, Mick R, Lichtenstein GR. Pediatric Crohn's disease: risk factors for postoperative recurrence. *Am J Gastroenterol* 2001; **96**: 2169-2176 [PMID: 11467649 DOI: 10.1111/j.1572-0241.2001.03876.x]

88 **Bernell O**, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. *Ann Surg* 2000; **231**: 38-45 [PMID: 10636100]

89 **De Cruz P**, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn's disease: a systematic review. *Inflamm Bowel Dis* 2012; **18**: 758-777 [PMID: 21830279 DOI: 10.1002/ibd.21825]

90 **Fazio VW**, Marchetti F, Church M, Goldblum JR, Lavery C, Hull TL, Milsom JW, Strong SA, Oakley JR, Secic M. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. *Ann Surg* 1996; **224**: 563-71; discussion 571-3 [PMID: 8857860]

91 **He X**, Chen Z, Huang J, Lian L, Rouniyar S, Wu X, Lan P. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn's disease: a meta-analysis. *Dig Dis Sci* 2014; **59**: 1544-1551 [PMID: 24500450 DOI: 10.1007/s10620-014-3039-0]

92 **Simillis C**, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. *Dis Colon Rectum* 2007; **50**: 1674-1687 [PMID: 17682822]

93 **McLeod RS**, Wolff BG, Ross S, Parkes R, McKenzie M. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. *Dis Colon Rectum* 2009; **52**: 919-927 [PMID: 19502857 DOI: 10.1007/DCR.0b013e3181a4fa58]

94 **Van Assche G**, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.*J Crohns Colitis* 2010; **4**: 63-101 [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009]

95 **Choy PY**, Bissett IP, Docherty JG, Parry BR, Merrie A, Fitzgerald A. Stapled versus handsewn methods for ileocolic anastomoses. *Cochrane Database Syst Rev* 2011; : CD004320 [PMID: 21901690 DOI: 10.1002/14651858.CD004320.pub3]

96 **Resegotti A**, Astegiano M, Farina EC, Ciccone G, Avagnina G, Giustetto A, Campra D, Fronda GR. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn's disease surgery. *Dis Colon Rectum* 2005; **48**: 464-468 [PMID: 15719193]

97 **Muñoz-Juárez M**, Yamamoto T, Wolff BG, Keighley MR. Wide-lumen stapled anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn's disease. *Dis Colon Rectum* 2001; **44**: 20-5; discussion 25-6 [PMID: 11805559]

98 **Moran BJ**. Stapling instruments for intestinal anastomosis in colorectal surgery. *Br J Surg* 1996; **83**: 902-909 [PMID: 8813772]

99 **Yamamoto T**, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. *Dis Colon Rectum* 2000; **43**: 1141-1145 [PMID: 10950014]

100 **Alves A**, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. *Dis Colon Rectum* 2007; **50**: 331-336 [PMID: 17252288]

101 **Efron JE**, Young-Fadok TM. Preoperative optimization of Crohn's disease. *Clin Colon Rectal Surg* 2007; **20**: 303-308 [PMID: 20011426 DOI: 10.1055/s-2007-991029]

102 **Ambe R**, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn's disease: types, indications, comparisons, and safety. *J Gastrointest Surg* 2012; **16**: 209-217 [PMID: 21909847 DOI: 10.1007/s11605-011-1651-2]

103 **Yamamoto T**, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. *Dis Colon Rectum* 2007; **50**: 1968-1986 [PMID: 17762967]

104 **Bamford R,** Hay A, Kumar D. Resection leads to less recurrence than strictureplasty in a paediatric population with obstructive Crohn’s disease. *Surg Res Pract* 2014; **2014**: 709045 [PMID: 25374959 doi: 10.1155/2014/709045]

105 **Di Abriola GF**, De Angelis P, Dall'oglio L, Di Lorenzo M. Strictureplasty: An alternative approach in long segment bowel stenosis Crohn's disease. *J Pediatr Surg* 2003; **38**: 814-818 [PMID: 12720200 DOI: 10.1016/jpsu.2003.50173]

106 **Louis E**, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. *Gut* 2001; **49**: 777-782 [PMID: 11709511 DOI: 10.1136/gut.49.6.777]

107 **Hassan C**, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. *Aliment Pharmacol Ther* 2007; **26**: 1457-1464 [PMID: 17903236 DOI: 10.1111/j.1365-2036.2007.03532.x]

108 **Endo K**, Takahashi S, Shiga H, Kakuta Y, Kinouchi Y, Shimosegawa T. Short and long-term outcomes of endoscopic balloon dilatation for Crohn's disease strictures. *World J Gastroenterol* 2013; **19**: 86-91 [PMID: 23326167 DOI: 10.3748/wjg.v19.i1.86]

109 **Stienecker K**, Gleichmann D, Neumayer U, Glaser HJ, Tonus C. Long-term results of endoscopic balloon dilatation of lower gastrointestinal tract strictures in Crohn's disease: a prospective study. *World J Gastroenterol* 2009; **15**: 2623-2627 [PMID: 19496192 DOI: 10.3748/wjg.15.2623.]

110 **Keljo DJ**, Markowitz J, Langton C, Lerer T, Bousvaros A, Carvalho R, Crandall W, Evans J, Griffiths A, Kay M, Kugathasan S, LeLeiko N, Mack D, Mamula P, Moyer MS, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Hyams JS. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. *Inflamm Bowel Dis* 2009; **15**: 383-387 [PMID: 19023863 DOI: 10.1002/ibd.20767]

111 **Palder SB**, Shandling B, Bilik R, Griffiths AM, Sherman P. Perianal complications of pediatric Crohn's disease. *J Pediatr Surg* 1991; **26**: 513-515 [PMID: 2061798 DOI: 10.1016/0022-3468(91)90694-O]

112 **Eglinton TW**, Roberts R, Pearson J, Barclay M, Merriman TR, Frizelle FA, Gearry RB. Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. *Am J Gastroenterol* 2012; **107**: 589-596 [PMID: 22158027 DOI: 10.1038/ajg.2011.437]

113 **Hughes LE**. Clinical classification of perianal Crohn's disease. *Dis Colon Rectum* 1992; **35**: 928-932 [PMID: 1395978]

114 **Parks AG**, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. *Br J Surg* 1976; **63**: 1-12 [PMID: 1267867]

115 **Bell SJ**, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. *Aliment Pharmacol Ther* 2003; **17**: 1145-1151 [PMID: 12752351 DOI: 10.1046/j.1365-2036.2003.01561.x]

116 **Pikarsky AJ,** Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. *Arch Surg* 2002; **137**: 774-777 [PMID: 12093328 DOI: 10.1001/archsurg.137.7.774]

117 **Irvine EJ**. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. *J Clin Gastroenterol* 1995; **20**: 27-32 [PMID: 7884173]

118 **Fields S**, Rosainz L, Korelitz BI, Panagopoulos G, Schneider J. Rectal strictures in Crohn's disease and coexisting perirectal complications. *Inflamm Bowel Dis* 2008; **14**: 29-31 [PMID: 17886289]

119 **Bernstein LH**, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. *Gastroenterology* 1980; **79**: 357-365 [PMID: 7399243]

120 **Malchow H**, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterology* 1984; **86**: 249-266 [PMID: 6140202]

121 **Present DH**, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med* 1999; **340**: 1398-1405 [PMID: 10228190 DOI: 10.1056/NEJM199905063401804]

122 **Cezard JP**, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. *J Pediatr Gastroenterol Nutr* 2003; **36**: 632-636 [PMID: 12717087]

123 **Crandall W**, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. *J Pediatr Gastroenterol Nutr* 2009; **49**: 183-190 [PMID: 19561542 DOI: 10.1097/MPG.0b013e3181a70f21]

124 **Essary B**, Kim J, Anupindi S, Katz JA, Nimkin K. Pelvic MRI in children with Crohn disease and suspected perianal involvement. *Pediatr Radiol* 2007; **37**: 201-208 [PMID: 17180366 DOI: 10.1007/s00247-006-0372-2]

125 **de Ridder L**, Escher JC, Bouquet J, Schweizer JJ, Rings EH, Tolboom JJ, Houwen RH, Norbruis OF, Derkx BH, Taminiau JA. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. *J Pediatr Gastroenterol Nutr* 2004; **39**: 46-52 [PMID: 15187780]

126 **Kim MJ**, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. *Acta Paediatr* 2011; **100**: 451-455 [PMID: 20626362 DOI: 10.1111/j.1651-2227.2010.01938.x]

127 **Topstad DR**, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. *Dis Colon Rectum* 2003; **46**: 577-583 [PMID: 12792431]

128 **Domènech E,** Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? *Aliment Pharmacol Ther* 2005; **22**: 1107-1113 [PMID: 16305724 DOI: 10.1111/j.1365-2036.2005.02670.x]

129 **Thornton M**, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn's disease. *Dis Colon Rectum* 2005; **48**: 459-463 [PMID: 15719188]

130 **van der Hagen SJ**, Baeten CG, Soeters PB, Beets-Tan RG, Russel MG, van Gemert WG. Staged mucosal advancement flap for the treatment of complex anal fistulas: pretreatment with noncutting Setons and in case of recurrent multiple abscesses a diverting stoma. *Colorectal Dis* 2005; **7**: 513-518 [PMID: 16108891 DOI: 10.1111/j.1463-1318.2005.00850.x]

131 **Rius J**, Nessim A, Nogueras JJ, Wexner SD. Gracilis transposition in complicated perianal fistula and unhealed perineal wounds in Crohn's disease. *Eur J Surg* 2000; **166**: 218-222 [PMID: 10755336]

132 **Orkin BA**, Telander RL. The effect of intra-abdominal resection or fecal diversion on perianal disease in pediatric Crohn's disease. *J Pediatr Surg* 1985; **20**: 343-347 [PMID: 4045658]

133 **Moy J**, Bodzin J. Carbon dioxide laser ablation of perianal fistulas in patients with Crohn's disease: experience with 27 patients. *Am J Surg* 2006; **191**: 424-427 [PMID: 16490560 DOI: 10.1016/j.amjsurg.2005.10.050]

134 **Vitton V**, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn's anal fistulas with fibrin glue injection. *Aliment Pharmacol Ther* 2005; **21**: 1453-1457 [PMID: 15948812 DOI: 10.1111/j.1365-2036.2005.02456.x]

135 **Schwandner O**, Fuerst A. Preliminary results on efficacy in closure of transsphincteric and rectovaginal fistulas associated with Crohn's disease using new biomaterials. *Surg Innov* 2009; **16**: 162-168 [PMID: 19502244 DOI: 10.1177/1553350609338041]

136 **Asteria CR**, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. *Scand J Gastroenterol* 2006; **41**: 1064-1072 [PMID: 16938720 DOI: 10.1080/00365520600609941]

137 **Cho YB**, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. *Cell Transplant* 2013; **22**: 279-285 [PMID: 23006344 DOI: 10.3727/096368912X656045]

138 **Castellaneta SP**, Afzal NA, Greenberg M, Deere H, Davies S, Murch SH, Walker-Smith JA, Thomson M, Srivistrava A. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2004; **39**: 257-261 [PMID: 15319625]

139 **Loftus EV Jr.** Upper gastrointestinal tract Crohn’s disease. *Clin Perspect Gastroenterol* 2002; **5**: 188-191

140 **Kefalas CH**. Gastroduodenal Crohn's disease. *Proc (Bayl Univ Med Cent)* 2003; **16**: 147-151 [PMID: 16278730]

141 **Yamamoto T**, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease: clinicopathologic features and management. *Scand J Gastroenterol* 1999; **34**: 1019-1024 [PMID: 10563673]

142 **Gatt M**, Anderson AD, Reddy BS, Hayward-Sampson P, Tring IC, MacFie J. Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. *Br J Surg* 2005; **92**: 1354-1362 [PMID: 16237744 DOI: 10.1002/bjs.5187]

143 **Delaney CP**, Fazio VW, Senagore AJ, Robinson B, Halverson AL, Remzi FH. 'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. *Br J Surg* 2001; **88**: 1533-1538 [PMID: 11683754 DOI: 10.1046/j.0007-1323.2001.01905.x]

144 **Wind J**, Polle SW, Fung Kon Jin PH, Dejong CH, von Meyenfeldt MF, Ubbink DT, Gouma DJ, Bemelman WA. Systematic review of enhanced recovery programmes in colonic surgery. *Br J Surg* 2006; **93**: 800-809 [PMID: 16775831 DOI: 10.1002/bjs.5384]

145 **Walter CJ**, Collin J, Dumville JC, Drew PJ, Monson JR. Enhanced recovery in colorectal resections: a systematic review and meta-analysis. *Colorectal Dis* 2009; **11**: 344-353 [PMID: 19207699 DOI: 10.1111/j.1463-1318.2009.01789.x]

146 **Kariv Y**, Delaney CP, Senagore AJ, Manilich EA, Hammel JP, Church JM, Ravas J, Fazio VW. Clinical outcomes and cost analysis of a "fast track" postoperative care pathway for ileal pouch-anal anastomosis: a case control study. *Dis Colon Rectum* 2007; **50**: 137-146 [PMID: 17186427]

147 **Gouvas N**, Tan E, Windsor A, Xynos E, Tekkis PP. Fast-track vs standard care in colorectal surgery: a meta-analysis update. *Int J Colorectal Dis* 2009; **24**: 1119-1131 [PMID: 19415308 DOI: 10.1007/s00384-009-0703-5]

148 **West MA**, Horwood JF, Staves S, Jones C, Goulden MR, Minford J, Lamont G, Baillie CT, Rooney PS. Potential benefits of fast-track concepts in paediatric colorectal surgery. *J Pediatr Surg* 2013; **48**: 1924-1930 [PMID: 24074669 DOI: 10.1016/j.jpedsurg.2013.02.063]

149 **Turner D**, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, Dias JA, Bronsky J, Braegger CP, Cucchiara S, de Ridder L, Fagerberg UL, Hussey S, Hugot JP, Kolacek S, Kolho KL, Lionetti P, Paerregaard A, Potapov A, Rintala R, Serban DE, Staiano A, Sweeny B, Veerman G, Veres G, Wilson DC, Ruemmele FM. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr* 2012; **55**: 340-361 [PMID: 22773060 DOI: 10.1097MPG.0b013e3182662233]

150 **Goodhand J**, Hedin CR, Croft NM, Lindsay JO. Adolescents with IBD: the importance of structured transition care. *J Crohns Colitis* 2011; **5**: 509-519 [PMID: 22115368 DOI: 10.1016/j.crohns.2011.03.015]

151 **Crowley R**, Wolfe I, Lock K, McKee M. Improving the transition between paediatric and adult healthcare: a systematic review. *Arch Dis Child* 2011; **96**: 548-553 [PMID: 21388969 DOI: 10.1136/adc.2010.202473]

**P-Reviewer:** Andersen NN, Bokemeyer B, Radmard AR **S-Editor:** Ma YJ

 **L-Editor: E-Editor:**



**Figure 1 Ileal pouch anal anastomosis being fashioned, stapling a small bowel J-pouch, and its anastomosis to the anus and sphincter complex.**



**Figure 2 Straight ileo-rectal anastomosis.**



**Figure 3 Ileocaecal resection for terminal ileal Crohn’s disease.**